FTC Wants More Info On Genzyme/Ilex Merger; Firms See No Delay In Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The inquiry is spurred by independent studies on Ilex’ leukemia agent Campath for transplant treatment, which could overlap with Genzyme’s Thymoglobulin.
You may also be interested in...
Genzyme Proposes To "Disentangle" Schering From Campath Marketing Deal
The proposal is an effort to win FTC approval for Genzyme's $1 bil. bid for Ilex. Genzyme expects to issue 22 mil. shares as part of the deal, but the dilution may be offset by stronger than previously expected performance of Renagel, Fabrazyme and Cerezyme.
Genzyme Proposes To "Disentangle" Schering From Campath Marketing Deal
The proposal is an effort to win FTC approval for Genzyme's $1 bil. bid for Ilex. Genzyme expects to issue 22 mil. shares as part of the deal, but the dilution may be offset by stronger than previously expected performance of Renagel, Fabrazyme and Cerezyme.
Genzyme To Acquire Ilex Oncology
Genzyme will pay $1 bil. for its first oncology therapeutic agent through the acquisition of Ilex Oncology